Dicot Pharma is developing LIB-01, a long-acting oral medication for erectile dysfunction that aims to provide a therapeutic effect lasting at least 28 days with minimal side effects. This addresses the limitations of existing treatments, which often have a maximum efficacy of 36 hours and do not work for up to 35% of men with erectile issues.
Funding
$12.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing erectile dysfunction (ED) treatments have limitations, including a maximum efficacy of 36 hours and ineffectiveness for up to 35% of men. Many men in Sweden do not seek medical help for ED due to the stigma associated with the condition.
Solution
Dicot Pharma is developing LIB-01, a long-acting oral medication for ED designed to provide a therapeutic effect lasting at least 28 days. LIB-01 aims to address the shortcomings of current treatments by offering a significantly extended duration of action and potentially working for individuals who do not respond to existing therapies. The medication is currently undergoing clinical studies.
Target Audience
The primary target audience includes men experiencing erectile dysfunction and physicians specializing in sexual medicine who seek new and improved treatment options.
Features
- Long-acting oral medication with a therapeutic effect lasting at least 28 days.
- Designed to have minimal side effects compared to existing treatments.
- Aims to be effective for a broader range of men with ED, including those who do not respond to current medications.